The RNA-Binding Protein Musashi-1 Regulates Proteasome Subunit Expression in Breast Cancer- and Glioma-Initiating Cells

Abstract

Cancer stem cells (CSCs) or tumor-initiating cells, similar to normal tissue stem cells, rely on developmental pathways, such as the Notch pathway, to maintain their stem cell state. One of the regulators of the Notch pathway is Musashi-1, a mRNA-binding protein. Musashi-1 promotes Notch signaling by binding to the mRNA of Numb, the negative regulator of Notch signaling, thus preventing its translation. CSCs have also been shown to downregulate their 26S proteasome activity in several types of solid tumors, thus making them resistant to proteasome-inhibitors used as anticancer agents in the clinic. Interestingly, the Notch pathway can be inhibited by proteasomal degradation of the Notch intracellular domain (Notch-ICD); therefore, downregulation of the 26S proteasome activity can lead to stabilization of Notch-ICD. Here, we present evidence that the downregulation of the 26S proteasome in CSCs constitutes another level of control by which Musashi-1 promotes signaling through the Notch pathway and maintenance of the stem cell phenotype of this subpopulation of cancer cells. We demonstrate that Musashi-1 mediates the downregulation of the 26S proteasome by binding to the mRNA of NF-YA, the transcriptional factor regulating 26S proteasome subunit expression, thus providing an additional route by which the degradation of Notch-ICD is prevented, and Notch signaling is sustained. Stem Cells 2014;32:135–144

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 01, 2014
Source ID
10.1002/stem.1537

Entities

People

  • Chann Lagadec
  • Erina Vlashi
  • Frank Pajonk
  • Mabel Chan
  • Patricia Frohnen
  • Yazeed Alhiyari

Organizations

  • National Cancer Institute
  • UCLA David Geffen School of Medicine
  • University of California

Tags

Fields of Study

  • Biology

Readers

  • Molecular Biology and Genetics

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech